Yesterday, Bristol-Myers Squibb Co. (BMY) extended its cash tender offer to purchase all outstanding shares of Medarex Inc. (MEDX) by two days to Aug. 26. Bristol-Myers offered to buy Medarex for $16 per share, or $2.1 billion in July. However, less than 9% of Medarex’s outstanding shares have been tendered till now. Last week, antitrust regulators approved the deal.

With the acquisition of Medarex, Bristol-Myers will get the UltiMAb Human Antibody Development System, which produces high affinity, human antibodies for use in a broad range of therapeutic areas Incorporatedluding immunology and oncology. It will also obtain Medarex’s next-generation Antibody-Drug Conjugate  technology, which is a novel and proprietary platform that could open new fields in cancer treatment.

Medarex’s has seven antibodies in clinical trials under its sole funding and is developing three other antibodies under partnership contracts. Importantly, Bristol-Myers will acquire full ownership and rights to ipilimumab, which, if approved, could be a major contributor to the company’s future growth.

Ipilimumab, a novel immunotherapy, is currently in phase III development for metastatic melanoma. It is also undergoing phase II study for lung cancer and other late-stage studies for adjuvant melanoma and hormone-refractory prostate cancer.

The Medarex acquisition should help Bristol-Myers offset the loss of revenue after its key product Plavix loses exclusivity in 2011. The company is building a strong pipeline of candidates to boost sales in the coming years. Additionally, management is working on reducing costs and shedding less profitable and non-core businesses.

We currently have an Outperform rating on the stock. We believe that the current price represents an attractive entry point for long-term investors.

Zacks Investment Research
View original at: Zacks.com News Feed

1. (BMY) Bristol-Myers Squibb’s Plavix Patent Getting ReviewBristol-Myers Squibb (BMY) announced that its lead drug, Plavix, will be reviewed by the U.S....
2. (BMY) Bristol-Myers Squibb Co. announced Medarex Acquisition Cleared ReviewBristol-Myers Squibb Co. (BMY) yesterday announced that the regulatory review period for its cash tender...
3. (BMY) Bristol-Myers Squibb Co. – Growth And Income – Zacks Rank BuyBristol-Myers Squibb Co. (BMY) recently declared a quarterly dividend of 31 cents per share, noting...
4. (BMY) Bristol Myers Squibb – IPO offering of its Mead Johnson Nutrition (MJN) businessBristol Myers Squibb Co. (BMY) boasts a solid record of exceeding analysts’ earnings expectations, missing...
5. (BMY) Bristol-Myers Squibb – forecast represents a 23% increase over last year’s earningsBristol-Myers Squibb Co. (BMY) offers a rewarding dividend yield of 5.5%. Lately, the company has...
6. (BMY) Bristol-Myers Squibb – forecast represents a 23% increase over last year’s earningsBristol-Myers Squibb Co. (BMY) has been outperforming the Dow Jones ($DJI), S&P 500 (SPX) and...

Search Posts by Tag: BMY | Bristol-Myers Squibb Company | Medarex Inc | MEDX | Drug Manufacturers - Major | Healthcare

RSS Feeds by Tag: BMY | Bristol-Myers Squibb Company | Medarex Inc | MEDX | Drug Manufacturers - Major | Healthcare |

Other Posts by: vitalstocks | RSS Feed for this author